In the clinical trials that lead to<unk> 's FDA approval, the most commonly reported adverse effects were infections (56%), high blood pressure (41%), infusion reactions (27%), and fever (24%). Serious adverse effects occurred in about half of the subjects studied in the clinical trial that led to its FDA approval.
Emapalumab
Olaratumab
Ustekinumab
Evolocumab
Anifrolumab
Dupilumab
Sarilumab
Burosumab